explore -WSS

explore

author：knowledge 2025-09-28 12:08:51 - browse：427

Anna Yeo/STAT

Recently approved gene therapies offer patients one-time, potentially curative treatments for genetic diseases such as sickle cell anemia and beta thalassemia. But “one-time” miracle solutions can often be multi-month affairs, require millions of dollars, and cause painful side effects. What if that doesn’t have to be the case?

In utero gene editing, or prenatal somatic cell genome editing, envisions treating a fetus diagnosed with a genetic disease before birth, thereby preventing that entire protocol and the onset of symptoms in the first place. It would also challenge the need for the ethically fraught enterprise of embryo editing, as the treatment would only make edits in the DNA of the individual fetus — edits which would not be passed on in a heritable way.

Watch this video to learn more about in utero gene editing, how it works, and why scientists believe it might be an advantageous approach to treating certain genetic diseases.

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Seattle police shoot person suspected in downtown stabbing

hotspot

explore

WSS

States increasingly look to regulate hospital facility fees

Celebrate National Dole Whip Day for 3 days this week at Disney

Meta's Zuckerberg and Chan on track to put $50 billion into science

CDC recommends rationing of RSV shot due to shortages

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

Researchers separate signal from noise in heart wearable data

leisure time

explore

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Maker of FluMist seeks to allow at

Novavax promises a turnaround & Lilly roils the obesity market

First Opinion Podcast: How to protect health care in times of war

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

WHO may add ‘noma' to its list of neglected tropical diseases

Activists slam private health insurers over coverage restrictions

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

New air purifier tech could be key to improving indoor air quality

Couple fighting to bring baby home from Mexico are finally reunited

focus

Maker of FluMist seeks to allow at

India sets sights on home

Man who had jail sentence commuted by Trump arrested again

Eli Lilly to pay $200M for Beam’s stake in gene

WHO may add ‘noma' to its list of neglected tropical diseases

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

hotspot

explore

Wikipedia

hotspot